CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 415 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03449953
NCT03449953N/AActive

Critical Care Outcomes of Patients With Hematologic Malignancy and Hematopoietic Cell Transplantation

Mount Sinai Hospital, Canada·observational·Posted Feb 28, 2018·Updated Nov 27, 2024

In Brief

An observational study for Hematologic Malignancy and Stem Cell Transplant. Active but no longer recruiting, targeting 415 participants across 13 sites.

Detailed Summary

Hematologic malignancy patients are admitted to ICU in increasing numbers. Successful ICU intervention has led to an increasing number of ICU survivors; however, there is a lack of information available about these patients' long term survival and quality of life. There is little Canadian data regarding ICU survival and regarding 1-year survival and functional outcomes in this group of patients. Over 500 patients are admitted annually to Canadian ICUs with an underlying hematologic malignancy or stem cell transplant, yet there is a paucity of up to date long-term outcome data. This information will facilitate a better understanding who would best benefit from critical care interventions and the impact of critical illness on their level of function at 1 year as well as survival.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesCanada
Collaborators--

Timeline

N/AActive
2018201920202021202220232024202520262027
First PostedFeb 28, 2018
Enrollment StartFeb 26, 2018
Primary CompletionDec 31, 2025
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 8.3 years ago